These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 3055921)

  • 61. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy.
    Vega GL; Grundy SM
    JAMA; 1990 Dec; 264(21):2759-63. PubMed ID: 2232062
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study.
    Chucrallah A; De Girolami U; Freeman R; Federman M
    Eur Neurol; 1992; 32(5):293-6. PubMed ID: 1521554
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study.
    Avins AL; Manos MM; Ackerson L; Zhao W; Murphy R; Levin TR; Watson DJ; Hwang PM; Replogle A; Levine JG
    Drug Saf; 2008; 31(4):325-34. PubMed ID: 18366243
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Worldwide experience with simvastatin/lovastatin.
    Walker JF
    Eur Heart J; 1992 Jul; 13 Suppl B():21-2. PubMed ID: 1644097
    [No Abstract]   [Full Text] [Related]  

  • 67. [Personal experience with lovastatin, a HMG-CoA reductase inhibitor (Mevacor, MSD) in the treatment of hypercholesterolemia].
    Vaverková H; Skottová N; Pudilová L; Horcicka V; Jezdinský J; Trtková M
    Vnitr Lek; 1991 May; 37(5):463-9. PubMed ID: 1842144
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Side effects of statins--prevalence, relevance, consequences.
    Sinzinger H
    Wien Klin Wochenschr; 2002 Nov; 114(21-22):887-8. PubMed ID: 12528318
    [No Abstract]   [Full Text] [Related]  

  • 69. Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol.
    Pearson TA
    Am J Cardiol; 2000 Dec; 86(12A):57L-61L. PubMed ID: 11374858
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia.
    Cressman MD; Hoogwerf BJ; Moodie DS; Olin JW; Weinstein CE
    Cleve Clin J Med; 1988; 55(1):93-100. PubMed ID: 3277742
    [No Abstract]   [Full Text] [Related]  

  • 72. HMG-CoA reductase inhibitors, gemfibrozil, and myopathy.
    Tobert JA
    Am J Cardiol; 1995 Apr; 75(12):862. PubMed ID: 7717303
    [No Abstract]   [Full Text] [Related]  

  • 73. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART).
    Elkind MS; Sacco RL; Macarthur RB; Peerschke E; Neils G; Andrews H; Stillman J; Corporan T; Leifer D; Liu R; Cheung K
    Cerebrovasc Dis; 2009; 28(3):266-75. PubMed ID: 19609078
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rhabdomyolysis and pancreatitis associated with coadministration of danazol 600 mg/d and lovastatin 40 mg/d.
    Hsieh CY; Chen CH
    Clin Ther; 2008 Jul; 30(7):1330-5. PubMed ID: 18691993
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Hypothyroidism and lovastatin-induced myositis].
    Rodríguez Framil M; Martínez Rey C; Alende Sixto MR; Torre Carballada JA
    An Med Interna; 2005 May; 22(5):252-3. PubMed ID: 16089017
    [No Abstract]   [Full Text] [Related]  

  • 76. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.
    Grimbert S; Pessayre D; Degott C; Benhamou JP
    Dig Dis Sci; 1994 Sep; 39(9):2032-3. PubMed ID: 8082513
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lovastatin for adult patients with dengue: protocol for a randomised controlled trial.
    Whitehorn J; Van Vinh Chau N; Truong NT; Tai LT; Van Hao N; Hien TT; Wolbers M; Merson L; Dung NT; Peeling R; Simmons C; Wills B; Farrar J
    Trials; 2012 Oct; 13():203. PubMed ID: 23114081
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lovastatin and myopathy.
    Tobert JA
    Am J Med; 1994 Mar; 96(3):300-1. PubMed ID: 8154521
    [No Abstract]   [Full Text] [Related]  

  • 79. Preclinical evaluation of lovastatin.
    MacDonald JS; Gerson RJ; Kornbrust DJ; Kloss MW; Prahalada S; Berry PH; Alberts AW; Bokelman DL
    Am J Cardiol; 1988 Nov; 62(15):16J-27J. PubMed ID: 3055920
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.
    Vuppalanchi R; Teal E; Chalasani N
    Am J Med Sci; 2005 Feb; 329(2):62-5. PubMed ID: 15711421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.